Gandeeva Raises $40M In Series A Funding To Develop Novel Therapies Based On Precision Imaging Of Protein-Drug Interactions
Gandeeva Raises $40M In Series A Funding To Develop Novel Therapies Based On Precision Imaging Of Protein-Drug Interactions
01/31/22, 1:00 PM
Location
vancouverMoney raised
$40 million
Round Type
series a
Gandeeva Therapeutics, a precision biotechnology company harnessing the power of cryogenic electron microscopy (cryo-EM) and machine learning to develop novel therapeutics at an accelerated pace, today announced it has raised US$40 million in Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures, Amplitude Ventures and Air Street Capital.
Company Info
Location
vancouver, washington, united states
Additional Info
Gandeeva™ is a precision biotechnology company harnessing the power of cryo-electron microscopy (cryo-EM) and machine learning to advance drug discovery and development at scale. Gandeeva Founder and CEO, Sriram Subramaniam is recognized internationally for his leadership in driving the cryo-EM resolution revolution and for innovations in 3D electron microscopic imaging. Gandeeva seeks to achieve transformative societal impact on public health by revolutionizing drug discovery and by lowering risks of late-stage clinical failures. Gandeeva is based in Vancouver, Canada. For more information, visit www.gandeeva.com or follow @Gandeeva_Tx on Twitter.